Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
View Patent ↗There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognize α 2 β 1 for infectivity of the cells. There are also provided methods for screening viruses for use in a method of the invention as well as pharmaceutical compositions for use in the methods.
1. A method for treating abnormal cells in a mammal comprising administering to the mammal an effective amount of an echovirus, which recognizes integrin α 2 β 1 for infectivity of the cells such that at least one of the cells are killed by the virus, wherein the abnormal cell is a cancer cell expressing α 2 β 1 .
2. The method according to claim 1 further comprising subjecting the mammal to more than one treatment with the virus, and wherein the virus in each of the treatments has the same or different serotypes.
3. The method according to claim 1 , wherein the virus is EV1 or EV8.
4. The method according to claim 1 , wherein the virus is modified to express the peptide motif RGD on its viral capsid surface.
5. The method according to claim 4 , wherein the virus maintains the echovirus serotype.
6. The method according to claim 5 wherein the virus is a modified form of EV1 or EV8.
7. The method according to claim 1 wherein the virus is administered to the mammal in combination with a second virus which infects the abnormal cells.
8. The method according to claim 7 wherein the abnormal cells express ICAM-1 and the second virus recognizes ICAM-1 for infectivity of the abnormal cells.
9. The method according to claim 8 wherein the second virus is a Coxsackievirus or a modified form thereof.
10. The method according to claim 9 wherein the Coxsackievirus is a Coxsackievirus serotype selected from A13, A15, A18 and A21.
11. The method according to claim 1 wherein the abnormal cells are cancer cells.
12. The method according to claim 11 wherein the cancer cells are ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.
13. The method according to claim 1 wherein the abnormal cells have up-regulated expression of integrin α 2 β 1 .
14. The method according to claim 1 wherein the virus is administered topically, systemically or intratumorally to the mammal.
15. A method for inducing an immune response in a mammal against abnormal cells expressing integrin α 2 β 1 , the method comprising infecting abnormal cells in the mammal with an echovirus, thereby causing lysis of at least one of the cells and inducing an immune response in the mammal against the abnormal cells, wherein the abnormal cell is a cancer cell expressing α 2 β 1 .
16. The method according to claim 15 , wherein the virus is EV1 or EV8.
17. The method according to claim 15 wherein the virus is modified to express the peptide motif RGD on its viral capsid surface.
18. The method according to claim 17 , wherein the virus maintains the echovirus serotype.
19. The method according to claim 17 wherein the modified echovirus is a modified form of EV1 or EV8.
20. The method according to claim 15 wherein the abnormal cells have up-regulated expression of integrin α 2 β 1 .
21. The method according to claim 15 wherein the virus is administered to the mammal in combination with a second virus which infects the abnormal cells.
22. The method according to claim 21 wherein the abnormal cells express ICAM-1 and the second virus recognizes ICAM-1 for infectivity of the abnormal cells.
23. The method according to claim 22 wherein the second virus is a Coxsackievirus or modified form thereof.
24. The method according to claim 23 wherein the Coxsackievirus is a Coxsackievirus serotype selected from A13, A15, A18 and A21.
25. The method according to claim 15 wherein the abnormal cells are cancer cells.
26. The method according to claim 25 wherein the cancer cells are ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.
27. The method according to claim 15 wherein the virus is administered topically, systemically or intratumorally to the mammal.